Senesco Technologies to Present at the 14th Annual Meeting of American Society of Gene and Cell Therapy
May 19 2011 - 9:00AM
Business Wire
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE
Amex: SNT), announced today that it will deliver a poster
presentation at the 14th Annual Meeting of the American Society of
Gene & Cell Therapy. The conference will be held May 18-21,
2011 at the Washington State Convention Center in Seattle,
Washington. The Company will present during the Late Abstract
Session II, which will begin Friday, May 20, at 4:40 P.M. Eastern
Time. The poster presentation, entitled “Optimization of DNA to
siRNA Ratio in SNS01 – an eIF5A-Based Gene Therapy Nanoparticle
Designed for the Treatment of Multiple Myeloma”, will
describe the properties of SNS01-T and be delivered by Catherine
Taylor, from Senesco CSO John Thompson’s research laboratory at the
University of Waterloo in Ontario, Canada. Additional details about
the conference can be found at: http://www.asgct.org
About Senesco Technologies, Inc.
Senesco Technologies is leveraging proprietary technology that
regulates programmed cell death, or apoptosis. Accelerating
apoptosis may have application in treating cancer, while delaying
apoptosis may have application in certain inflammatory and ischemic
diseases. The Company is preparing to initiate a clinical study in
multiple myeloma with its lead therapeutic candidate SNS01-T.
Senesco has already partnered with leading-edge companies engaged
in agricultural biotechnology, and is entitled to earn research and
development milestones and royalties if its gene-regulating
platform technology is incorporated into its partners’
products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; the timing and success of the
Company’s preliminary studies and preclinical research; competition
and the timing of projects and trends in future operating
performance, the Company’s ability to comply with the continued
listing standards of the NYSE/AMEX, as well as other factors
expressed from time to time in the Company’s periodic filings with
the Securities and Exchange Commission (the "SEC"). As a result,
this press release should be read in conjunction with the Company’s
periodic filings with the SEC. The forward-looking statements
contained herein are made only as of the date of this press
release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Senesco (AMEX:SNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Jul 2023 to Jul 2024